Cartilage regeneration research in 2026 is an active field, and the published results so far are mixed. The largest randomized, placebo-controlled trial of adipose-derived cells for knee osteoarthritis reported a negative primary endpoint, with the placebo group scoring numerically better. This guide covers that trial, the studies still running, and what “being studied” does and does not mean.
TLDR: Several cell and tissue approaches to joint disease are under investigation, and adipose-derived cells are one of them. ADIPOA2 did not meet its primary endpoint: 47.3 percent of the cell group versus 54.8 percent of the placebo group were strict responders at six months, and the authors concluded that a single injection did not significantly improve pain and function. Other trials continue in China, South Korea, Denmark, and the United States. No adipose-derived product is FDA approved for any joint condition, and banking adipose tissue does not enroll anyone in a trial or guarantee eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat is a connector service linking patients and providers to a U.S. tissue bank. Save My Fat does not provide FDA-approved treatments or cures and does not guarantee eligibility, access, or clinical benefit. Adipose tissue and stromal vascular fraction are investigational and not FDA approved, and no adipose-derived product is approved for osteoarthritis or any other joint condition. This content is for educational purposes only, and readers should consult their own licensed healthcare professionals before acting on it.
If your knee hurts on stairs, the internet hands you a great deal of confident language. Clinic pages describe cell injections as though the science were settled. The published record is less tidy, and the most important recent number points the other way.
In the December 2025 issue of Annals of the Rheumatic Diseases, the ADIPOA2 investigators reported their primary endpoint. The trial did not meet it. The placebo group had a numerically higher responder rate than the cell group.
Research has not stopped. But a patient reading about this field in 2026 deserves the negative result up front, not buried under a list of ongoing studies. This guide gives both, with registry numbers you can check yourself.
What Cartilage Regeneration Research in 2026 Actually Covers
The phrase names a research field. It does not name an available outcome. Registered studies test different materials against different comparators, and most measure pain and function scores.
The materials under study include culture expanded adipose-derived mesenchymal stromal cells, microfragmented adipose tissue, stromal vascular fraction, bone marrow concentrate, and umbilical cord tissue cells. Comparators include placebo, saline, sodium hyaluronate, and corticosteroid injection. Readers tracking the field can review our orthobiologics research overview.
None of it is approved. The FDA’s approved cellular and gene therapy products list contains no adipose-derived product for any joint condition, and its consumer alert on regenerative medicine products names arthritis among the conditions these products are not approved for.
The Largest Placebo-Controlled Adipose Knee Trial Was Negative
ADIPOA2 is the largest randomized, placebo-controlled trial of adipose-derived cells in knee osteoarthritis with a published primary endpoint, and that endpoint was negative. Registered as NCT02838069, it was a Phase 2b trial run by University Hospital Montpellier with 17 collaborators. It tested autologous adipose-derived mesenchymal stromal cells, culture expanded, as a single intra-articular knee injection at 2 million or 10 million cells, against placebo, in mild to moderate knee osteoarthritis.
The trial began on September 20, 2016 and completed in March 2024, and the publication reports 97 patients analyzed. The primary endpoint was strict OARSI/OMERACT responder status at six months.
The published result reads: “After 6 months, treatment with ADSC versus placebo injection, 26 patients (47.3%) versus 23 patients (54.8%) were strict OARSI/OMERACT responders (relative risk 0.86 [95% CI: 0.58-1.28]; P =.46).” In plain numbers, 47.3 percent of the cell group and 54.8 percent of the placebo group met the responder definition. The placebo arm did numerically better.
The conclusion in the published ADIPOA2 report is equally direct: “Among patients with symptomatic mild-to-moderate knee OA, a single intra-articular injection..did not significantly improve pain and function.” The registry record carries no posted results, so the finding sits in the publication.
This is a negative trial and should be read as one. Do not confuse it with ADIPOA, an earlier Phase 1 study registered as NCT01585857 with 18 participants. Patients following this space can also review our summary of osteoarthritis trial results.
What the Ongoing Knee and Hip Trials Are Comparing
Ongoing does not mean working. It means enrolled, or still running toward an answer nobody has yet. The table lists registered adipose-related joint studies recruiting or active as of July 27, 2026.
| Study | Phase | Status | Country | What is being compared |
|---|---|---|---|---|
| NCT06570291 | Phase 3 | Recruiting | China | Allogeneic adipose MSC versus sodium hyaluronate |
| NCT04368806 | Phase 2b/3a | Recruiting | South Korea and United States | Autologous adipose MSC versus placebo |
| NCT05933434 | Phase 1/2 | Recruiting | Denmark | Allogeneic adipose MSC versus saline |
| NCT04427930 | Phase 3 extension | Active, not recruiting | South Korea | Long term extension of autologous adipose MSC |
| NCT06121882 | Phase 3 | Active, not recruiting | United States | Microfragmented adipose tissue versus saline |
| NCT05553132 | Phase 1 | Active, not recruiting | United States | Autologous chondrons with allogeneic adipose MSC in fibrin glue, hip |
| NCT03608579 | Phase 1 | Active, not recruiting | United States | Culture expanded autologous adipose MSC, hip osteoarthritis |
| NCT04440189 | Phase 3 | Active, not recruiting | Not listed | Autologous adipose stromal vascular fraction, knee osteoarthritis |
Three of the eight are recruiting and five are running without enrolling. Enrollment sits between 15 and 520 participants, and several remain Phase 1. The record used here does not list a country for NCT04440189, whose sponsor is GID BIO.
How Adipose Approaches Compare With Other Cells Under Investigation
The strongest head to head available is MILES, NCT03818737. Emory University ran it as a Phase 3 trial in the United States with 475 participants and four arms: a corticosteroid control, bone marrow concentrate, adipose stromal vascular fraction, and umbilical cord tissue mesenchymal stromal cells, in unilateral knee osteoarthritis. It is completed, with results posted to the registry. Two Italian studies compare the sources directly: NCT06040957 at Istituto Ortopedico Rizzoli and NCT05447767 at Istituto Clinico Humanitas.
The tissue source argument is often oversold. Adipose is easier to obtain in volume, but a same-patient comparison published in Cells Tissues Organs found “No significant differences were observed for yield of adherent stromal cells, growth kinetics, cell senescence, multi-lineage differentiation capacity, and gene transduction efficiency.” Our overview of orthopedic applications covers the wider picture.
What “Being Studied” Means on ClinicalTrials.gov
Registry language is precise, and patients lose money reading it loosely. The ClinicalTrials.gov glossary defines Recruiting as “The study is currently recruiting participants.” Active, not recruiting means the study is ongoing but no one new is being enrolled.
Completed means “The study has ended normally, and participants are no longer being examined or treated.” No status says anything about whether the intervention worked. A trial can be completed and negative at once, which is exactly what ADIPOA2 is.
Phase labels are misread just as often, and our guide to clinical trial phases explains what each phase is built to answer. Federal rules at 42 CFR Part 11 require registration within 21 days of the first participant and results generally within one year after primary completion.
Telling Research From Marketing
A registered trial has an NCT number, a named sponsor, a phase, a listed status, and a defined comparator. A clinic offer usually has a price and a testimonial. That difference is most of the test.
Enforcement makes it concrete. In a warning letter issued February 11, 2026, the FDA cited a Nevada clinic for marketing an umbilical cord derived product as an unapproved new drug, citing non-homologous use for cardiovascular disease and arthritis.
Patients who want to join research should start with the registry, not an advertisement, and our guide to finding legitimate trials walks through the steps. Bring the NCT number to a licensed orthopedic surgeon and ask what the trial compares and what its primary endpoint is.
Frequently Asked Questions
What cartilage regeneration approaches are currently in clinical trials?
Registered studies are evaluating culture expanded adipose-derived mesenchymal stromal cells, microfragmented adipose tissue, stromal vascular fraction, bone marrow concentrate, and umbilical cord tissue cells, mostly in knee and hip osteoarthritis. Comparators include placebo, saline, sodium hyaluronate, and corticosteroid injection. All of it is investigational, the evidence is preliminary, and a clinician should interpret any specific study for you.
Are any cartilage regeneration products FDA approved for treatment as of 2026?
No. No adipose-derived product is FDA approved for osteoarthritis or any other joint condition. Ryoncil is the first FDA-approved mesenchymal stromal cell therapy, approved December 18, 2024. It is allogeneic and bone marrow derived, and its indication is steroid-refractory acute graft versus host disease in pediatric patients 2 months and older, not any joint condition.
How do adipose-derived cell approaches compare with other methods being studied?
The comparison is not settled. MILES, NCT03818737, is a completed 475-participant Phase 3 trial with four arms including adipose stromal vascular fraction, bone marrow concentrate, and umbilical cord tissue cells, and its results are posted to the registry. A same-patient laboratory study found no significant per-cell differences between adipose and bone marrow.
What does published research show about safety in early trials?
Early phase trials exist mainly to assess safety and tolerability, which is why the phase label matters. Findings vary by product, dose, and route, so no general statement covers them all. Registered studies can also be terminated, and federal rules require a posted reason. Read the specific record with an orthopedic surgeon.
How can patients find legitimate cartilage regeneration clinical trials?
Start at ClinicalTrials.gov, search by condition and intervention, then filter by recruiting status. Read the sponsor, the phase, the comparator, and the primary endpoint before contacting anyone. Confirm the listed site is a real institution, and have a licensed physician confirm eligibility before you travel or spend money.
What separates real cartilage regeneration research from unproven clinic marketing?
Research has a registered protocol, a control group, a pre-specified primary endpoint, and a result that gets posted even when it is negative. Marketing has testimonials, urgency, and a price list. If a clinic cannot give you an NCT number and name its comparator, you are not looking at a trial.
Key Takeaways
Cartilage regeneration research in 2026 is real, ongoing, and unfinished. The most important published result for adipose-derived cells in the knee is a negative one. In ADIPOA2, 47.3 percent of the cell group and 54.8 percent of the placebo group were strict responders at six months, a relative risk of 0.86 with a P value of.46, and the authors concluded that a single intra-articular injection did not significantly improve pain and function.
Eight registered adipose-related joint studies are recruiting or active across four countries, and MILES, the completed four-arm head to head at Emory, has results posted to the registry. No adipose-derived product is FDA approved for any joint condition, the evidence remains preliminary, and outcomes cannot be predicted for any individual. Banking adipose tissue is a storage decision that does not enroll anyone in a trial or guarantee eligibility, access, or clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Patients considering adipose tissue banking for potential future use can review current pricing or contact our team with questions about the collection process.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including orthopedic surgery input is required before publication. Please consult your orthopedic surgeon before making any decisions about banking, treatment, or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: adipose stem cell trials.
